Galenical forms of beta-2-mimetics for administration perlingually and sublingually

• US 5,080,903 A
• Filed: 09/24/1990
• Issued: 01/14/1992
• Est. Priority Date: 09/02/1987
• Status: Expired due to Fees

• Current Assignee: Medibrevex SA
• Original Assignee: Societe Civile DITE "Medibrevex"
• Inventors: Robert, Serge, Ayache, Jean-Jacques, Ayache, Josiane, Pedrali, Patrick, Bruttmann, Georges
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): AZPURU, CARLOS A
• Application Number:
  US07/587,592
• Time in Patent Office: 477 Days
• Field of Search: 424/474, 424/484, 424/488, 424/465
• US Class Current: 424/433
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61P 25/02 for peripheral neuropathies

Abstract

New galenical forms for administering beta-2-mimetics comprising a support conditioned to be placed into the sublingual and perlingual cavity of the mouth, the support made of a pharmaceutically acceptable compound which disintegrates under the action of saliva and progressively releases a controlled amount of the beta-2-mimetics into the sublingual and perlingual cavity of the mouth.

Claims

1. A method for administering beta-2-mimetics sublingually or perlingually comprising introducing into the sublingual or perlingual cavity of the mouth, a pharmaceutical composition comprising an effective amount of a beta-2-mimetic in a solid support which disintegrates rapidly under the action of saliva and progressively releases a controlled amount of said beta-2-mimetic into the sublingual or perlingual cavity of the mouth, and retaining said pharmaceutical composition in place in said sublingual or perlingual cavity until the composition has decomposed in the mouth.

2. The method according to claim 1 wherein said beta-2-mimetic is salbutamol sulfate.

3. A method for treating a patient suffering from a dyspneic respiratory disease by administering a beta-2-mimetic sublingually or perlingually comprising introducing into the sublingual or perlingual cavity of the mouth of said patient, a pharmaceutical composition comprising an effective amount of a beta-2-mimetic in a solid support which disintegrates rapidly under the action of saliva and progressively releases a controlled amount of said beta-2-mimetic into the sublingual and perlingual cavity of the mouth, and retaining said pharmaceutical composition in place in said sublingual or perlingual cavity until the composition has decomposed in the mouth.

4. The method according to claim 3 wherein said beta-2-mimetic is salbutamol sulfate.

5. The method according to claim 3 wherein said support is in divided form.

6. The method according to claim 3 wherein said support comprises a mixture of saccharose and lactose.